Why the study?
Whether metabolic flexibility in non-ischaemic cardiomyopathy correlates with reverse remodelling is unknown, prompting investigation into whether CRT acutely changes cardiac substrate uptake and translates to reverse remodelling.
Does cardiac resynchronization therapy alter cardiac substrate uptake and correlate with reverse remodelling in non-ischaemic cardiomyopathy?
Does cardiac resynchronization therapy alter cardiac substrate uptake and correlate with reverse remodelling in non-ischaemic cardiomyopathy?
CRT acutely alters the metabolic phenotype of non-ischaemic cardiomyopathy towards physiological fatty acid uptake, which correlates with long-term reverse remodelling.
Answers are grounded in this paper and cite their sources.
May link CRT metabolic shifts to reverse remodeling in non-ischaemic cardiomyopathy; hypothesis-generating and requires prospective validation.
BACKGROUND AND AIMS: Cardiac resynchronization therapy (CRT) produces long-term reverse remodelling which requires greater adenosine triphosphate delivery to the contractile machinery. Whilst the heart retains some metabolic flexibility in non-ischaemic cardiomyopathy, whether this correlates with reverse remodelling is unknown. This study investigated whether CRT acutely changes cardiac substrate uptake, and whether this translates to favourable reverse remodelling. METHODS: The effect of CRT on cardiac substrate uptake was assessed via direct coronary flow and arteriovenous measurements, with metabolomic/lipidomic analysis on infusions of insulin/glucose and intralipid. Cardiac function was assessed with left ventricular pressure-volume loops during implantation, and cardiac magnetic resonance before and 6 months following CRT, with and without biventricular pacing. RESULTS: Regardless of substrate infusion, CRT acutely improved stroke work without increasing O2 uptake on both insulin/glucose (by 34%, P = .05) and intralipid (by 36%, P = .03). This was followed by increased fatty acid (FA) uptake on insulin/glucose (R = 0.89, P = .03) and increased β-hydroxybutyrate uptake (R = 0.81, P = .05) during intralipid infusion. After 6 months, there was a 48% (P < .001) reduction in left ventricular end diastolic volume, beyond that achievable by acutely shortening or lengthening QRS duration. Reverse remodelling significantly correlated with increased FA uptake with CRT on insulin/glucose (R = 0.71, P = .05) driven by long and medium chain uptake, and increased ketone uptake with CRT on intralipid (R = 0.79, P = .05). CONCLUSIONS: CRT acutely alters the metabolic phenotype of non-ischaemic cardiomyopathy towards a more physiological picture of FA uptake which correlates with reverse remodelling. Retained metabolic flexibility may therefore be critical for subsequent reverse remodelling.
No takes yet. Share an insight, caveat, or question.
Green et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: